ReviewCancers2025
Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Unlocking the brain: Biodistribution insights into tween 80 nanoliposomes in healthy brains.International journal of pharmaceutics: X · 2026Article
- Perfluoroether Peptide-Modified Artificial Viral Capsid for Enhanced Doxorubicin Delivery to Liver Cancer Cells.ACS omega · 2026Article
- 5-FU chemotherapy induces functional CD7Science China. Life sciences · 2026Article
- Polymeric Nano Drug Delivery Systems for Overcoming Tumor Microenvironment-Mediated Drug Resistance.Pharmaceutics · 2026Review
- Phototherapeutic β-Cyclodextrin-Branched Polymer Releasing Nitric Oxide with Fluorescent Self-Reporting and Its Combination with Doxorubicin.Biomacromolecules · 2026Article
- Mycoendophytic-Derived Green Resveratrol-Conjugated Silver Nanoparticles Inhibit the Proliferation of Human Epidermoid Carcinoma A-431 Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- NF-κB Signaling in Prostate Cancer Progression: Inflammatory Mediators, Survival Pathways, and Regulatory Axes.Cancers · 2026Review
- mPEG-functionalized polyadipate triblock copolymers as promising nanocarriers for the controlled delivery of therapeutic agents in breast cancer treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
- Chitosan-coated mesoporous silica nanoparticles for pH-responsive doxorubicin delivery in head and neck cancer.Frontiers in bioengineering and biotechnology · 2026Article
- Polymer-doxorubicin Conjugates: Redefining Chemotherapy for Breast Cancer.Mini reviews in medicinal chemistry · 2026Article
- Emerging roles of spexin in cardiovascular homeostasis.Frontiers in cardiovascular medicine · 2026Review
- Development and Antitumor Evaluation of Doxorubicin-Loaded Two-Layered Sheets for Local Chemotherapy via Direct Drug Application to the Tumor Surface.Pharmaceutics · 2025Article
- An overview of advanced nanocarrier systems for Ibrutinib delivery: overcoming pharmacokinetic barriers and enabling targeted cancer therapy.International journal of pharmaceutics: X · 2025Review
- Theranostics in the management of colorectal cancer.Discover nano · 2025Review
- Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesEffective and targeted delivery of doxorubicin (DOX) remains a significant challenge due to its dose-limiting cardiotoxicity and systemic side effects. Liposomal formulations like Doxil
methodsThis review is organized into two key sections. The first section provides a comprehensive overview of DOX, including its mechanism of action, clinical challenges, and the limitations of current chemotherapy approaches. The second section highlights recent advances in polymeric nanocarriers for DOX delivery, focusing on polymeric micelles as well as other promising systems like hydrogels, dendrimers, polymersomes, and polymer-drug conjugates.
resultsInitial discussions explore current strategies enhancing DOX's clinical translation, including methods to address cardiotoxicity and multidrug resistance. The latter part presents recent studies that report improved drug loading efficiency in polymeric nanocarriers through techniques such as core/shell modifications, enhanced hydrophobic interactions, and polymer-drug conjugation.
conclusionsDespite notable progress in polymeric nanocarrier-based DOX delivery, challenges like limited circulation time, immunogenicity, and manufacturing scalability continue to hinder clinical application. Continued innovation in this field is crucial for the development of safe, effective, and clinically translatable polymeric nanocarriers for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.